Browse > Article
http://dx.doi.org/10.5012/bkcs.2010.31.9.2649

Preparation of 125  

Kim, Byoung-Soo (Radiopharmaceuticals Research Team, Korea Institute of Radiological and Medical Sciences)
Kim, Eun-Jung (Radiopharmaceuticals Research Team, Korea Institute of Radiological and Medical Sciences)
Lee, Hae-June (Laboratory of Radiation Effects, Korea Institute of Radiological and Medical Sciences)
Han, Sang-Jin (Radiopharmaceuticals Research Team, Korea Institute of Radiological and Medical Sciences)
Choi, Tae-Hyun (Radiopharmaceuticals Research Team, Korea Institute of Radiological and Medical Sciences)
Lee, Yun-Sil (Laboratory of Radiation Effects, Korea Institute of Radiological and Medical Sciences)
Cheon, Gi-Jeong (Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences)
Publication Information
Bulletin of the Korean Chemical Society / v.31, no.9, 2010 , pp. 2649-2655 More about this Journal
Abstract
$PKC{\delta}$-catalytic V5 Heptapeptide (FEQFLDI, FP7) interacts with heat shock protein 27 (HSP27) and inhibits HSP27-mediated resistance to cell death against various stimuli including radiation therapy. Here, we prepared radio-iodinated heptapeptide and further investigated its uptake properties in HSP27 expression cells. Peptide sequence of FP7 and a negative control peptide (WSLLEKR, QP7) was modified by substituting their C-terminus residue to tyrosine (FP6Y and QP6Y) to label radio-iodine. Iodinated peptides were confirmed by LC mass analysis with cold iodine reaction mixture. Accumulation of [$^{125}I$]iodo-FP6Y and [$^{125}I$]iodo-QP6Y in NCI-H1299 cell line, with higher level of HSP27, and NCI-H460 cell line, with lower level of HSP27, was measured by NaI(Tl) scintillation counter. The modification of substituting C-terminus residue of FP7 to tyrosine (FP6Y) did not affect its interaction with HSP27. Accumulation of [$^{125}I$]iodo-FP6Y in NCI-H1299 cells was 3 fold higher than in NCI-H460 cells. The novel radio-iodinated FP6Y would be used as a tracer for targeting HSP27 protein.
Keywords
$PKC{\delta}$-V5 Heptapeptide; HSP27; Radio-iodination;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Loot, A. E.; van Buiten, A.; Roks, A. J. M.; Henning, R. H. J. Pharmacol. Toxicol. Methods 2005, 51, 51-55.   DOI
2 Blower, P. J.; Puncher, M. R.; Kettle, A. G.; George, S.; Dorsch, S.; Leak, A.; Naylor, L. H.; O’Doherty, M. J. Eur. J. Nucl. Med. 1998, 25, 101-108.   DOI
3 Park, S. H.; Lee, S. J.; Chung, H. Y.; Kim, T. H.; Cho, C. K.; Yoo, S. Y. Radiat. Res. 2000, 153, 318-326.   DOI
4 Tai, H. H. ; Korsch, B.; Chey, W. Y. Anal. Biochem. 1975, 69, 34-42.   DOI
5 Tai, C. L.; Tai, H. H. Prostaglandins. Leukot. Med. 1984, 14, 243-254.   DOI
6 Tai, H. H.; Yuan, B. Anal. Biochem. 1978, 87, 343- 349.   DOI
7 Tashtoush, B. M.; Traboulsi, A. A.; Dittert, L.; Hussain, A. A. Anal. Biochem. 2001, 288, 16-21.   DOI
8 Vergote, V.; Baert, B.; Vandermeulen, E.; Peremans, K.; van Bree, H.; Slegers, G.; Burvenich, C.; Spiegeleer, B. D. J. Pharm. Biomed. Anal. 2008, 46, 127-136.   DOI
9 Inui, K. I.; Terada, T.; Masuda, S.; Saito, H. Nephrol. Dial. Transplant. 2000, 15, 11-13.
10 Garrido, C.; Gurbuxani, S.; Ravagnan, L.; Kroemer, G. Biochem. Biophys. Res. Commun. 2001, 286, 433-442.   DOI
11 Ciocca, D. R.; Oesterreich, S.; Chamness, G. C.; McGuire, W. L.; Fuqua, S. A. J. Natl. Cancer Inst. 1993, 85, 1558-1570.   DOI
12 Jaattela, M. Int. J. Cancer 1995, 60, 689693.
13 Garrido, C.; Fromentin, A.; Bonnotte, B.; Favre, N.; Moutet, M.; Arrigo, A. P. Cancer Res. 1998, 58, 5495-5499.
14 Cornford, P. A.; Dodson, A. R.; Parsons, K. F.; Desmond, A. D.; Woolfenden, A.; Fordham, M. Cancer Res. 2000, 60, 7099-7105.
15 van de Vijver, M. J.; He, Y. D.; van’t Veer, L. J.; Dai, H.; Hart, A. A.; Voskuil, D. W. N. Engl. J. Med. 2000, 34, 1999-2009.
16 van’t Veer, L. J.; Dai, H.; van de Vijver, M. J.; He, Y. D.; Hart, A. A.; Mao, M. Nature 2002, 415, 530-536.   DOI   ScienceOn
17 Garrido, C.; Brunet, M.; Didelot, C.; Zermati, Y.; Schmitt, E.; Kroemer, G. Cell Cycle 2006, 5, 2592-2601.   DOI
18 Didelot, C.; Schmitt, E.; Brunet, M.; Maingret, L.; Parcellier, A.; Garrido, C. Handb. Exp. Pharmacol. 2006, 172, 171-198.   DOI
19 Bruey, J. M.; Ducasse, C.; Bonniaud, P.; Ravagnan, L.; Susin, S. A.; Diaz-Latoud, C. Nat. Cell Biol. 2000, 2, 645-652.   DOI
20 Watanabe, T.; Ono, Y.; Taniyama, Y.; Hazama, K.; Igarashi, K.; Ogita, K. Proc. Natl. Acad. Sci. USA 1992, 89, 10159-10163.   DOI
21 Miyamoto, A.; Nakayama, K.; Imaki, H.; Hirose, S.; Jiang, Y.; Abe, M. Nature 2002, 416, 865-869.   DOI
22 Illera, V. A.; Perandones, C. E.; Stunz, L. L.; Mower, D. A.; Ashman, R. F. J. Immunol. 1993, 151, 2965-2973.
23 Lucas, M.; Sanchez-Margalet, V. Gen. Pharmacol. 1995. 265, 881-887.
24 Lu, Z.; Hornia, A.; Jiang, Y. W.; Zang, Q.; Ohno, S.; Foster, D. A. Mol. Cell Bio. 1997, 17, 3418-3428
25 Salacinski, P. R. P.; McLean, C.; Sykes, J. E. C.; Clement-Jones, V. V.; Lowry, P. J. Anal. Biochem. 1981, 117, 136-146.   DOI
26 Lee, Y. J.; Lee, D. H.; Cho, C. K.; Bae, S., Jhon, G. J.; Lee, S. J. J. Biol. Chem. 2005, 280, 18108-18119   DOI
27 Kim, E. H.; Lee, H. J.; Lee, D. H.; Bae, S.; Soh, J. W.; Jeoung, D. Cancer Res. 2007, 67, 6333-6341.   DOI
28 Hunter, W. M.; Greenwood, F. C. Nature 1962, 194, 495-496.   DOI
29 Marchalonis, J. J. Biochem. J. 1969, 113, 299-305.
30 Ritossa, F. Experimentia 1962, 18, 571-573.   DOI